- Home
- KMDA
KMDA
Kamada Ltd.
as 12-18-2024 1:38pm EST
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
| Founded: | 1990 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 349.6M | IPO Year: | N/A |
| Target Price: | $14.50 | AVG Volume (30 days): | 30.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.27 | EPS Growth: | 124.29 |
| 52 Week Low/High: | $4.74 - $6.53 | Next Earning Date: | 11-13-2024 |
| Revenue: | $158,380,000 | Revenue Growth: | 4.52% |
| Revenue Growth (this year): | 15.38% | Revenue Growth (next year): | 6.18% |
Latest Kamada Ltd. News
KMDA Breaking Stock News: Dive into KMDA Ticker-Specific Updates for Smart Investing
GuruFocus.com
a month ago
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ...
Associated Press Finance
a month ago
Kamada: Q3 Earnings Snapshot
GlobeNewswire
a month ago
Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance
GlobeNewswire
a month ago
Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024
GlobeNewswire
a month ago
Kamada to Present at the Stifel 2024 Healthcare Conference
GlobeNewswire
3 months ago
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston
Insider Monkey
4 months ago
Kamada Ltd. (KMDA): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
Zacks Small Cap Research
4 months ago
KMDA: Revenues Up 13% YoY; Adjusted EBITDA Up 51% YoY…
Compare KMDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KMDA Kamada Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.